Welcome to our dedicated page for Xenon Pharmaceuticals news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceuticals stock.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) is a pioneering biopharmaceutical company headquartered in Vancouver, British Columbia. Focused on neurology, Xenon leverages its proprietary discovery platform, termed 'extreme genetics', to develop innovative medications. The company’s approach involves studying families with severe phenotypes to identify single-gene defects, which offer insights into human biology and serve as potential drug targets.
Xenon’s development pipeline targets a range of neurological disorders, particularly epilepsy and depression. The flagship product, XEN1101, is a potent, selective potassium channel opener currently in various phases of clinical trials for epilepsy and major depressive disorder (MDD). Xenon has ongoing Phase 3 trials for XEN1101 in focal onset seizures (X-TOLE2, X-TOLE3) and primary generalized tonic-clonic seizures (X-ACKT). The drug has shown promising efficacy in reducing seizures and improving quality of life in long-term extension studies.
Additionally, Xenon is exploring XEN1101's potential in treating MDD, with a Phase 3 program expected to begin in 2024. Recent interim data from the X-NOVA Phase 2 trial revealed significant improvements in depression symptoms, supporting further development for this indication. Xenon’s pre-clinical work includes investigations into Nav1.1 and Nav1.7 potentiators for various neurological conditions.
Key developments include a partnership with Neurocrine Biosciences to develop XEN901 (NBI-921352) for epilepsy. Xenon's financial stability, robust clinical pipeline, and strategic collaborations position it for continued growth and innovation in neurology-focused therapeutics.
Recent Achievements:
- Strong presence at AES 2023 with multiple presentations on XEN1101
- Presented new data from the Phase 2b X-TOLE trial demonstrating significant seizure freedom rates
- Expanded open-label extension study collecting over 500 patient years of data
- Announced positive topline results from X-NOVA Phase 2 trial for MDD
- Ongoing collaboration with Icahn School of Medicine for additional MDD studies
For more updates and detailed information, visit the official website.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022. The company will conduct one-on-one investor meetings and a virtual fireside chat.
The chat is scheduled for 5:00-5:30 pm ET and will be presented by Ian Mortimer, the President and CEO. Attendees can access details and webcasts on the company’s website after the event.
Xenon is focused on developing innovative treatments for neurological disorders, particularly epilepsy.
Xenon Pharmaceuticals (Nasdaq:XENE) announced a significant regulatory milestone in its collaboration with Neurocrine Biosciences (Nasdaq:NBIX), resulting in a $15 million aggregate payment to Xenon. The FDA has accepted a protocol amendment that permits inclusion of pediatric patients aged 2-11 in the Phase 2 study of NBI-921352 for SCN8A developmental and epileptic encephalopathy. The payment consists of $6.75 million in cash and an $8.25 million equity investment at a premium price of $31.855 per share. This collaboration aims to enhance epilepsy treatment options for young patients.
Xenon Pharmaceuticals (Nasdaq:XENE) announced its key milestones for 2022, focusing on its lead product, XEN1101, which showed strong efficacy in a Phase 2b clinical trial for focal epilepsy. Plans include an FDA meeting in Q2 2022 and initiating a Phase 3 program later in the year. The company also aims to explore XEN1101 for major depressive disorder. Ongoing pediatric trials for XEN496 are expected to complete in early 2023. Collaborations with Neurocrine Biosciences and Pacira BioSciences are also highlighted, with potential milestone payments pending.
Xenon Pharmaceuticals (Nasdaq:XENE) announced promising results from the Phase 2b X-TOLE trial of XEN1101 for focal epilepsy, with statistically significant seizure reduction (p<0.001) across all dose groups. The 25 mg and 20 mg doses achieved median reductions of 52.8% and 46.4% in monthly seizures, respectively. The trial also demonstrated efficacy for difficult-to-treat patients. Xenon plans a Phase 3 trial and has long-term studies underway, reflecting strong potential for XEN1101 in market.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has announced its participation in the Annual Meeting of the American Epilepsy Society (AES 2021), highlighting significant updates on its neurology programs. CEO Ian Mortimer emphasized the advancement of XEN1101 and XEN496, with presentations scheduled to showcase Phase 2b clinical trial results and pre-clinical data on epilepsy treatments. A conference call is set for December 3, 2021, to discuss these results. The company aims to address unmet medical needs in epilepsy through innovative therapies.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced that CEO Ian Mortimer and CFO Sherry Aulin will speak at three upcoming virtual investor conferences. The Guggenheim 3rd Annual Neuro/Immunology Conference will take place on November 15, 2021, featuring one-on-one meetings. The Stifel 2021 Virtual Healthcare Conference is scheduled for November 17, 2021, including a fireside chat at 1:20 pm ET. Lastly, the Jefferies London Healthcare Conference is set for November 18, 2021, with an on-demand fireside chat starting at 8:00 am GMT. For updates, visit investor.xenon-pharma.com.
Xenon Pharmaceuticals (Nasdaq:XENE) reported promising insights from its Phase 2b X-TOLE clinical trial for XEN1101, showing significant reductions in focal seizure frequency among adult patients. The therapy is designed for easy administration with once-daily dosing. With $249.6 million in cash and equivalents as of September 30, 2021, and anticipated cash flow until at least 2024, the company is set for the initiation of its Phase 3 trial in adult focal epilepsy in late 2022. Total revenue for Q3 2021 reached $8.1 million, up from $6.6 million a year earlier.
Xenon Pharmaceuticals (Nasdaq:XENE) will report its third quarter 2021 financial results on November 10, 2021, after U.S. market close. A live conference call and webcast will take place at 4:30 pm ET to discuss these results and provide a corporate update. Investors can access the webcast through the company's website. As a clinical-stage biopharmaceutical company, Xenon focuses on developing therapies for neurological disorders, particularly epilepsy, addressing significant unmet medical needs.
Xenon Pharmaceuticals Inc. has successfully closed its underwritten public offering of 10,000,000 common shares, including 1,525,423 shares from the underwriters’ option, and pre-funded warrants for 1,694,915 shares. The shares were priced at $29.50 each, with pre-funded warrants at $29.4999. The gross proceeds from this offering totaled approximately $345 million, prior to expenses. The offering followed an effective shelf registration statement filed with the SEC on October 4, 2021.
Xenon Pharmaceuticals has announced a public offering of 8,474,577 common shares and 1,694,915 pre-funded warrants, priced at $29.50 and $29.4999 respectively. The offering aims to raise approximately $300 million in gross proceeds, which will support the company's clinical stage developments. The offering is set to close on or about October 8, 2021. The underwriters have a 30-day option to purchase an additional 1,525,423 shares at the offering price. Jefferies, SVB Leerink, Stifel, and RBC Capital Markets are leading the offering.
FAQ
What is the current stock price of Xenon Pharmaceuticals (XENE)?
What is the market cap of Xenon Pharmaceuticals (XENE)?
What does Xenon Pharmaceuticals specialize in?
What is the focus of Xenon’s proprietary discovery platform?
What is XEN1101?
What are the recent achievements of Xenon Pharmaceuticals?
Who are Xenon’s strategic partners?
What are Xenon’s key products in the pipeline?
What is the status of the XEN1101 epilepsy trials?
How can I contact Xenon Pharmaceuticals for investor information?
Where is Xenon Pharmaceuticals headquartered?
What is the significance of Xenon’s pre-clinical work?
